Variant Libraries 

Dedicated to creating well-designed, highly diverse libraries to ensure that you uncover more of what you want and only what you want.

Access to Expertise

Our years of molecular biology expertise combined with the Twist DNA Synthesis Silicon platform ensures that you receive the exact library you want with no compromises.

Protein Engineering

Target Selection and Antibody Optimization

Synthetic Biology

Complex Custom Libraries

Twist’s proprietary oligo synthesis technology offers a unique approach to library creation. The silicon-based synthesis platform generates high-quality oligo pools, which are used to build fully-customized, user-defined variant libraries on a single chip. Twist's unparalleled platform also enables the creation of thousands to billions of specific variants. You can be assured exactly what you design is exactly what you get.

Complex Custom Libraries
High Diversity Variant Domains

High Diversity Variant Domains

Twist has developed high fidelity methods for precisely splicing large pools of oligonucleotides (with composition and length variation) to create NGS verified combinatorial diversity of up to 10^10 unique variants within a single domain. Every variant is designed in-silico and screened prior to synthesis, eliminating unwanted sequence bias, premature stop codons, and undesirable motifs.

 

Learn more about Libraries Technology

What Scientists Have to Say
The Library we’ve asked for was very complex. Based on our analysis, the library we received was excellent. What we’ve designed is what we’ve obtained.
Dr. Sandrine Moutel
Manager of Technology • Institut Curie Recombinant Antibody Platform and TAb-IP Platform
Working with Twist was a great experience. Twist’s support was amazing. We have performed the first validation selections which looks promising.
Dr. Ahuva Nissim
Professor in Antibody and Therapeutic Engineering • Queen Mary University of London
We have performed the first selections using the Fab and scFv libraries. No problem in both cases, we got clones and some look really promising.
Pierre Martineau
Deputy Director, Cancer Research Institute of Montpellier • Founder and Scientific Advisor, iMAb company